

CONMED CORP
Form 4
June 07, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
GOLDEN JO ANN

(Last) (First) (Middle)

C/O CONMED CORP, 525
FRENCH ROAD

(Street)

UTICA, NY 13502-5994

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED CORP [CNMD]

3. Date of Earliest Transaction
(Month/Day/Year)
06/05/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | Code | V Amount (A) or (D) Price | | | |
| Common Stock | 06/05/2013 | | M | 2,500 A \$ 30.04 | 12,413 | D | |
| Common Stock | 06/05/2013 | | F | 2,349 D \$ 31.98 | 10,064 | D | |
| Common Stock | 06/05/2013 | | M | 2,500 A \$ 25.7 | 12,564 | D | |
| Common Stock | 06/05/2013 | | F | 2,010 D \$ 31.98 | 10,554 | D | |
| Common Stock | 06/05/2013 | | M | 500 A \$ 16.46 | 11,054 | D | |

Edgar Filing: CONMED CORP - Form 4

| | | | | | | | |
|--------------|------------|---|-------|---|----------|--------|---|
| Common Stock | 06/05/2013 | F | 258 | D | \$ 31.98 | 10,796 | D |
| Common Stock | 06/05/2013 | M | 1,000 | A | \$ 27.63 | 11,796 | D |
| Common Stock | 06/05/2013 | F | 864 | D | \$ 31.98 | 10,932 | D |
| Common Stock | 06/05/2013 | M | 1,000 | A | \$ 26.09 | 11,932 | D |
| Common Stock | 06/05/2013 | F | 816 | D | \$ 31.98 | 11,116 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | Am or Nur of Sha | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|------------------|-------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | |
| Sars (Stock Appreciation Rights) | \$ 30.04 | 06/05/2013 | | M | 2,500 | <u>(1)</u> 05/18/2017 | 05/18/2017 | Common Stock | 2,500 |
| Sars (Stock Appreciation Rights) | \$ 25.7 | 06/05/2013 | | M | 2,500 | <u>(1)</u> 05/16/2018 | 05/16/2018 | Common Stock | 2,500 |
| Sars (Stock Appreciation Rights) | \$ 16.46 | 06/05/2013 | | M | 500 | <u>(2)</u> 06/01/2019 | 06/01/2019 | Common Stock | 500 |
| Sars (Stock Appreciation Rights) | \$ 27.63 | 06/05/2013 | | M | 1,000 | 06/01/2012 ⁽³⁾ | 06/01/2021 | Common Stock | 1,000 |
| Sars (Stock Appreciation Rights) | \$ 26.09 | 06/05/2013 | | M | 1,000 | 06/01/2013 ⁽³⁾ | 06/01/2022 | Common Stock | 1,000 |

Rights)

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| GOLDEN JO ANN C/O CONMED CORP 525 FRENCH ROAD UTICA, NY 13502-5994 | X | | | |

Signatures

Daniel S. Jonas for Jo Ann Golden by Power of Attorney

06/07/2013

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The stock appreciation rights ("SARs") were granted under the Company's 2007 Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 20% per year over a five year period, with any unvested SARs to vest upon the Director's termination of

(1) service provided the Director has completed one full year of service since the date of the award in which case the SARs shall be exercisable at any time prior to the expiration date of the SAR or within one year after the date of such termination, whichever period is shorter.

The stock appreciation rights ("SARs") were granted under the Company's 2007 Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 20% per year over a five year period, with any unvested SARs to vest upon the Director's termination of

(2) service provided the Director has completed one full year of service since the date of the award in which case the SARs shall be exercisable at any time prior to the expiration date of the SAR or within one year after the date of such termination, whichever period is shorter.

(3) The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.